83 related articles for article (PubMed ID: 19745651)
1. Overnight versus progressive conversion of multiple daily-dose divalproex to once-daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities?
Hellings JA; Barth FX; Logan M; Cook-Wiens G; Osorio I; Reed RC
J Clin Psychopharmacol; 2009 Oct; 29(5):492-5. PubMed ID: 19745651
[TBL] [Abstract][Full Text] [Related]
2. Extended-release divalproex in child and adolescent outpatients with epilepsy.
Kernitsky L; O'Hara KA; Jiang P; Pellock JM
Epilepsia; 2005 Mar; 46(3):440-3. PubMed ID: 15730542
[TBL] [Abstract][Full Text] [Related]
3. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
[TBL] [Abstract][Full Text] [Related]
4. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
Reed RC; Dutta S; Liu W
Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
[TBL] [Abstract][Full Text] [Related]
5. Seizure control and side-effect profile after switching adult epileptic patients from standard to extended-release divalproex sodium.
Pierre-Louis SJ; Brannegan RT; Evans AT
Clin Neurol Neurosurg; 2009 Jun; 111(5):437-41. PubMed ID: 19181439
[TBL] [Abstract][Full Text] [Related]
6. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up.
McCabe PH; Michel NC; McNew CD; Lehman EB
Epilepsy Behav; 2006 May; 8(3):601-5. PubMed ID: 16678766
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
Hirschfeld RM; Bowden CL; Vigna NV; Wozniak P; Collins M
J Clin Psychiatry; 2010 Apr; 71(4):426-32. PubMed ID: 20361904
[TBL] [Abstract][Full Text] [Related]
8. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials.
Smith MC; Centorrino F; Welge JA; Collins MA
Epilepsy Behav; 2004 Oct; 5(5):746-51. PubMed ID: 15380129
[TBL] [Abstract][Full Text] [Related]
9. Tolerability of oral loading of divalproex sodium in the treatment of acute mania.
Martinez JM; Russell JM; Hirschfeld RM
Depress Anxiety; 1998; 7(2):83-6. PubMed ID: 9614597
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.
Sachs G; Chengappa KN; Suppes T; Mullen JA; Brecher M; Devine NA; Sweitzer DE
Bipolar Disord; 2004 Jun; 6(3):213-23. PubMed ID: 15117400
[TBL] [Abstract][Full Text] [Related]
11. Divalproex-ER pharmacokinetics in older children and adolescents.
Dutta S; Zhang Y; Conway JM; Sallee FR; Biton V; Reed MD; Kearns GL
Pediatr Neurol; 2004 May; 30(5):330-7. PubMed ID: 15165635
[TBL] [Abstract][Full Text] [Related]
12. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
Reed RC; Dutta S
Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
[TBL] [Abstract][Full Text] [Related]
13. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
Boggs JG; Preis K
Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
[TBL] [Abstract][Full Text] [Related]
14. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
15. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia.
Citrome L; Tremeau F; Wynn PS; Roy B; Dinakar H
J Clin Psychopharmacol; 2004 Jun; 24(3):255-9. PubMed ID: 15118478
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
17. Rapid oral loading of extended release divalproex in patients with acute mania.
Miller BP; Perry W; Moutier CY; Robinson SK; Feifel D
Gen Hosp Psychiatry; 2005; 27(3):218-21. PubMed ID: 15882770
[TBL] [Abstract][Full Text] [Related]
18. Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
Sussman N; Mullen J; Paulsson B; Vågerö M
J Affect Disord; 2007; 100 Suppl 1():S55-63. PubMed ID: 17383736
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Zhang Y; Lee LL; O'Dea R
Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
[TBL] [Abstract][Full Text] [Related]
20. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
Dunbar F; Zhu Y; Brashear HR
Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
